Contravisory Investment Management Inc. Buys 23,682 Shares of Cencora, Inc. $COR

Contravisory Investment Management Inc. boosted its stake in Cencora, Inc. (NYSE:COR) by 451.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,926 shares of the company’s stock after purchasing an additional 23,682 shares during the quarter. Cencora comprises approximately 1.9% of Contravisory Investment Management Inc.’s portfolio, making the stock its 18th biggest holding. Contravisory Investment Management Inc.’s holdings in Cencora were worth $9,087,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Kestra Private Wealth Services LLC grew its stake in Cencora by 4.6% in the 1st quarter. Kestra Private Wealth Services LLC now owns 22,840 shares of the company’s stock worth $7,175,000 after buying an additional 997 shares in the last quarter. Brian Low Financial Group LLC raised its position in shares of Cencora by 11.3% during the 1st quarter. Brian Low Financial Group LLC now owns 4,794 shares of the company’s stock valued at $1,506,000 after buying an additional 486 shares in the last quarter. Fifth Third Wealth Advisors LLC raised its position in shares of Cencora by 9.7% during the 1st quarter. Fifth Third Wealth Advisors LLC now owns 2,847 shares of the company’s stock valued at $894,000 after buying an additional 251 shares in the last quarter. OP Asset Management Ltd bought a new stake in shares of Cencora during the 1st quarter worth $20,725,000. Finally, Apella Capital LLC lifted its holdings in shares of Cencora by 9.9% during the 1st quarter. Apella Capital LLC now owns 970 shares of the company’s stock worth $318,000 after acquiring an additional 87 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. William Blair assumed coverage on Cencora in a research note on Tuesday, April 28th. They issued a “market perform” rating on the stock. Bank of America lifted their price target on Cencora from $280.00 to $285.00 and gave the stock a “neutral” rating in a research note on Wednesday. Barclays cut their price objective on Cencora from $425.00 to $350.00 and set an “overweight” rating for the company in a report on Wednesday, June 10th. Evercore set a $360.00 price objective on Cencora in a research report on Wednesday, April 8th. Finally, Morgan Stanley set a $342.00 price objective on Cencora in a report on Friday, May 8th. Twelve investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Cencora currently has a consensus rating of “Moderate Buy” and a consensus price target of $367.75.

Insiders Place Their Bets

In related news, Director Lauren M. Tyler bought 550 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was bought at an average cost of $270.23 per share, for a total transaction of $148,626.50. Following the acquisition, the director directly owned 4,359 shares of the company’s stock, valued at $1,177,932.57. The trade was a 14.44% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.38% of the stock is owned by corporate insiders.

Cencora Price Performance

Shares of NYSE:COR opened at $287.55 on Friday. The stock has a market cap of $55.95 billion, a PE ratio of 22.05, a PEG ratio of 1.53 and a beta of 0.59. The company’s fifty day moving average is $281.44 and its 200 day moving average is $322.43. Cencora, Inc. has a 52 week low of $244.82 and a 52 week high of $377.54. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The business had revenue of $78.36 billion during the quarter, compared to the consensus estimate of $81.09 billion. During the same period in the prior year, the firm earned $4.42 earnings per share. The business’s revenue for the quarter was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Research analysts anticipate that Cencora, Inc. will post 17.79 earnings per share for the current year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend was Friday, May 15th. Cencora’s payout ratio is 18.40%.

Cencora announced that its board has authorized a share repurchase plan on Thursday, May 21st that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the company to reacquire up to 3.9% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s board believes its stock is undervalued.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.